Johnson & Johnson (JNJ) Income towards Parent Company (2009 - 2026)
Johnson & Johnson's (JNJ) quarterly Income towards Parent Company came in at $5.2 billion in Q1 2026, down 52.4% year-on-year from $11.0 billion in Q1 2025, and up 2.33% quarter-over-quarter from $5.1 billion in Q4 2025.
Johnson & Johnson (JNJ) Income towards Parent Company (2009 - 2026) Analysis & Trends
Johnson & Johnson has disclosed Income towards Parent Company across 17 years of filings, most recently posting $5.2 billion for Q1 2026.
- Income towards Parent Company for Q1 2026 came in at $5.2 billion, down 52.4% year-over-year; the trailing twelve-month figure through Mar 2026 was $21.0 billion (up 91.29% YoY), and the FY2023 annual result was $21.8 billion, up 1289.37% from the prior year.
- Income towards Parent Company came in at $5.2 billion for Q1 2026 at Johnson & Johnson, up from $5.1 billion in the prior quarter.
- In the past five years, Income towards Parent Company ranged from a high of $21.7 billion in Q4 2023 to a low of -$232.0 million in Q3 2023.
- The 4-year median for Income towards Parent Company is $578.0 million (2022), against an average of $4.3 billion.
- Peak annual rise in Income towards Parent Company reached 14575.0% in 2023, while the deepest fall reached 142.03% in 2023.
- Johnson & Johnson's Income towards Parent Company stood at $148.0 million in 2022, then plunged by 156.08% to -$83.0 million in 2023, then jumped by 6263.86% to $5.1 billion in 2025, then grew by 2.33% to $5.2 billion in 2026.
- The last three Income towards Parent Company figures came in at $5.2 billion (Q1 2026), $5.1 billion (Q4 2025), and $5.2 billion (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn |
| 10 | Novartis Ag | 109.78 Bn | 109.09 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 29, 2026 | 5.24 Bn |
| Dec 28, 2025 | 5.12 Bn |
| Sep 28, 2025 | 5.15 Bn |
| Jun 29, 2025 | 5.54 Bn |
| Mar 30, 2025 | 11.00 Bn |
| Dec 31, 2023 | -83.00 Mn |
| Oct 1, 2023 | 21.72 Bn |
| Jul 2, 2023 | -232.00 Mn |
| Apr 2, 2023 | 423.00 Mn |
| Jan 1, 2023 | 293.00 Mn |
| Oct 2, 2022 | 148.00 Mn |
| Jul 3, 2022 | 552.00 Mn |
| Apr 3, 2022 | 578.00 Mn |
| Oct 3, 2021 | 3.67 Bn |
| Jul 4, 2021 | 6.28 Bn |
| Apr 4, 2021 | 6.20 Bn |
| Jan 3, 2021 | 1.74 Bn |
| Sep 27, 2020 | 3.55 Bn |
| Jun 28, 2020 | 3.63 Bn |
| Mar 29, 2020 | 5.80 Bn |